Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes - Exact Sciences ( NASDAQ:EXAS ) , Boston Scientific ( NYSE:BSX )
Insulet Corp.'s PODD groundbreaking Omnipod 5 Automated Insulin Delivery ( "AID" ) system ( Omnipod 5 ) received the FDA's approval for use by type 2 diabetes patients ( ages 18 years and above ) .
| Ticker |
Sentiment |
Impact |
|
EXAS
|
Neutral
|
16 %
|
|
BSX
|
Neutral
|
8 %
|
|
PODD
|
Somewhat Bullish
|
24 %
|
